Immunotherapy for asthma.

Cell Mol Immunol · 2025 · PMC12660796 · PMID 41145900

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

One possibility for the lack of efficacy of Lebrikizumab in mild asthma patients might be that IL-13 may not be the cytokine responsible for the symptoms in such a patient population, and a role for IL-13 may be significant only in more severe forms of the disease [ 103 ].

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.